These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24305712)

  • 1. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
    Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
    Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
    Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
    Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
    Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
    J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
    Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
    J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
    Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
    Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
    Tunthanathip T; Sangkhathat S
    Clin Neurol Neurosurg; 2020 Apr; 191():105712. PubMed ID: 32036239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
    Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
    J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
    Kizilbash SH; Giannini C; Voss JS; Decker PA; Jenkins RB; Hardie J; Laack NN; Parney IF; Uhm JH; Buckner JC
    J Neurooncol; 2014 Oct; 120(1):85-93. PubMed ID: 24993250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
    Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
    J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic glioblastoma: an evaluation of IDH1 status and prognosis.
    Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG
    Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
    Fiorentino A; Balducci M; De Bonis P; Chiesa S; De Filippo L; Mangiola A; De Rose F; Autorino R; Rinaldi C; Fersino S; Diletto B; Matteucci P; Ciurlia E; Fusco V; Anile C; Valentini V
    Am J Clin Oncol; 2015 Feb; 38(1):23-7. PubMed ID: 23388566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
    Favero F; McGranahan N; Salm M; Birkbak NJ; Sanborn JZ; Benz SC; Becq J; Peden JF; Kingsbury Z; Grocok RJ; Humphray S; Bentley D; Spencer-Dene B; Gutteridge A; Brada M; Roger S; Dietrich PY; Forshew T; Gerlinger M; Rowan A; Stamp G; Eklund AC; Szallasi Z; Swanton C
    Ann Oncol; 2015 May; 26(5):880-887. PubMed ID: 25732040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatiotemporal Evolution of the Primary Glioblastoma Genome.
    Kim J; Lee IH; Cho HJ; Park CK; Jung YS; Kim Y; Nam SH; Kim BS; Johnson MD; Kong DS; Seol HJ; Lee JI; Joo KM; Yoon Y; Park WY; Lee J; Park PJ; Nam DH
    Cancer Cell; 2015 Sep; 28(3):318-28. PubMed ID: 26373279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.